Literature DB >> 31342822

Long non-coding RNA NORAD induces cell proliferation and migration in prostate cancer.

Haiyan Zhang1, Haixiang Guo1.   

Abstract

Entities:  

Keywords:  NORAD; apoptosis; long non-coding RNA; migration; proliferation; prostate cancer

Mesh:

Substances:

Year:  2019        PMID: 31342822      PMCID: PMC6726771          DOI: 10.1177/0300060519862076

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


× No keyword cloud information.

Introduction

Prostate cancer (PCA) is the most frequently occurring cancer in men, and the leading mortality risk to men’s health.[1,2] Moreover, the number of newly diagnosed cases of PCA is increasing in most countries.[3-5] Despite the treatment options currently available for patients with early-stage PCA, such as surgery and radiation therapy, the 5-year survival rate is very low for patients with later-stage disease.[6,7] Therefore, an understanding of the mechanisms of PCA development is urgently needed. Long noncoding RNAs (lncRNAs) are nonprotein coding RNAs >200 nucleotides in length.[8-10] Several lncRNAs, including GAS5,[11] LRIG3,[12] and DCTPP1,[13] were previously shown to participate in the progression of PCA. Recently, long noncoding RNA activated by DNA damage (NORAD) was reported to be overexpressed in a range of cancer types such as pancreatic cancer[14] and bladder cancer,[15] with high NORAD levels being associated with a low survival rate. NORAD induces the invasion and metastasis of pancreatic carcinoma cells, NORAD levels were found to be higher in colorectal cancer (CRC) tissues than in control samples,[16] and NORAD is required for CRC progression through the targeting of miR-202-5p.[17] However, the expression pattern and function of NORAD in PCA remain unknown. Therefore, the present study aimed to analyze the role of NORAD in PCA.

Materials and methods

Materials

The human PCA cell lines LNCaP, 22Rv1, PC-3, and DU145 and normal prostate epithelial cells (RWPE-1) were purchased from the American Type Culture Collection (Manassas, VA, USA). RPMI‐1640 medium was purchased from Thermo Fisher Scientific (Waltham, MA, USA) and Lipofectamine 2000 was purchased from Invitrogen (Carlsbad, CA, USA).

Cell culture

PCA cells were cultured in RPMI‐1640 medium with 10% fetal bovine serum (FBS) and 1% penicillin G and streptomycin (Gibco, Grand Island, NY, USA) in an atmosphere of 5% CO2 at 37°C. This study included no animal or human experiments, so ethical permission was not required.

Cell transfection

NORAD small interfering (si)RNA (si-NORAD) was provided by Heyuan (Shanghai, China). PCA cells (1 × 105) were seeded in 24-well plates. After 24 hours, they were transfected with 10 nM si-NORAD using 1 µl Lipofectamine 2000 according to the manufacturer’s protocol. They were then incubated for a further 48 hours before being harvested for further investigation.

Cell proliferation assay

PCA cell proliferation was assessed using a Cell Counting Kit (CCK)-8 assay (Dojindo Molecular Technologies, Inc., Kumamoto, Japan) according to the manufacturer’s instructions. Briefly, PCA cells (5 × 103) were added to each well of 96-well plates for 0 to 5 days, then 10 µl of CCK-8 reagent was added per well and incubated for 2 hours at 37°C. The absorbance of each well at 450 nm was analyzed by an enzyme immunoassay analyzer.

Annexin V- fluorescein isothiocyanate (FITC)/propidium iodide (PI) staining assay

The level of NORAD was measured 48 hours after transfection, and PC-3 and DU-145 cells were harvested for apoptosis assays. The PCA cell apoptosis rate was measured using an annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) apoptosis kit (BD Biosciences, San Diego, CA, USA) in accordance with the manufacturer’s instructions. At least 1 × 104 cells were dyed with Annexin V-FITC and PI for 15 minutes, then evaluated using a flow cytometer (BD Biosciences).

Migration assay

Cells (5 × 105) were plated into 6-well plates and grown to 90% confluence. A 35-mm scratch on the surface of the cells was generated using a plastic tip, then cells were cultured for a further 24 hours in new medium containing 0.5% FBS. Finally, scratch images were acquired using a microscope (Olympus, Tokyo, Japan).

Reverse transcription PCR

Total RNA was isolated using TRIzol reagent (Life Technologies, Shanghai, China). cDNA was synthesized using the Prime Script™ RT Reagent Kit (Takara, Dalian, China), then quantitative real-time (qRT)-PCR was performed with the VeriQuest SYBR Green qPCR Master Mix kit (Thermo Fisher Scientific) using GAPDH as an internal mRNA control. The relative level of NORAD was evaluated using the 2−ΔΔt method

Statistical analysis

Data were analyzed using SPSS 17.0 software (SPSS Inc., Chicago, IL, USA). The statistical significance of differences between groups was determined using t tests. Data are expressed as means ± standard deviations. Western blot findings were evaluated using Quantity One software (Bio-Rad, Kunming, China). P < 0.05 was considered significant.

Results

Analysis of NORAD expression in PCA cell lines

To study the effect of NORAD on PCA, we first detected NORAD levels by qRT-PCR in PCA cells. NORAD expression was significantly higher in the four human PCA cell lines than in control cells (Figure 1; P < 0.05). The highest expression of NORAD was detected in PC-3 and DU-145 cells (P < 0.01), so these were used in subsequent experiments.
Figure 1.

NORAD expression is higher in LNCaP, 22Rv1, PC-3, and DU145 cell lines than in healthy prostate epithelial cells. Data are representative of three experiments; results are means ± SD. *P < 0.05, **P < 0.01.

NORAD expression is higher in LNCaP, 22Rv1, PC-3, and DU145 cell lines than in healthy prostate epithelial cells. Data are representative of three experiments; results are means ± SD. *P < 0.05, **P < 0.01.

NORAD knockdown in PCA cells

To further investigate the role of NORAD in PCA, we established a PCA cell model by transfecting siRNA targeting NORAD. We used qRT-PCR to measure mRNA expression. As shown in Figure 2, NORAD mRNA expression was significantly reduced following siRNA transfection (P < 0.05), indicating that NORAD was downregulated in PC-3 and DU145 cell lines.
Figure 2.

NORAD was knocked down by siRNA in PC-3 and DU145 cells. qRT-PCR detected the inhibitory efficiency of siRNA and sicontrol. Data are representative of three experiments; results are means ± SD. *P < 0.05.

NORAD was knocked down by siRNA in PC-3 and DU145 cells. qRT-PCR detected the inhibitory efficiency of siRNA and sicontrol. Data are representative of three experiments; results are means ± SD. *P < 0.05.

Effects of NORAD on PC3 and DU145 cell proliferation

Next, we assessed the proliferation of PC-3 and DU145 cells after NORAD silencing. The CCK-8 assay showed that proliferation was significantly lower in the si-NORAD group than in the si-NC group (Figure 3a and b; P < 0.05 and 0.01). These results suggested that NORAD is involved in PCA cell proliferation.
Figure 3.

Knockdown of NORAD reduced PC-3 (a) and DU145 (b) cell proliferation according to a CCK-8 assay. Data are representative of three experiments; results are means ± SD. *P < 0.05, **P < 0.01.

Knockdown of NORAD reduced PC-3 (a) and DU145 (b) cell proliferation according to a CCK-8 assay. Data are representative of three experiments; results are means ± SD. *P < 0.05, **P < 0.01.

Effects of NORAD on PC3 and DU145 cell apoptosis rate

Apoptosis in PC-3 and DU145 cells was also assessed after NORAD silencing. Flow cytometry analysis revealed that NORAD knockdown cells had a significantly increased apoptosis rate compared with si-NC cells (Figure 4; P < 0.05). This indicated that NORAD is involved in PCA cell apoptosis.
Figure 4.

Knockdown of NORAD induced PC-3 and DU145 cell apoptosis according to an annexin V-FITC/PI assay. Data are representative of three experiments; results are means ± SD. *P < 0.05.

Knockdown of NORAD induced PC-3 and DU145 cell apoptosis according to an annexin V-FITC/PI assay. Data are representative of three experiments; results are means ± SD. *P < 0.05.

Effect of NORAD on PC3 and DU145 cell migration

To assess the metastasis of PC-3 and DU145 cells after NORAD silencing, the wound healing assay was used. The PCA cell migration rate was significantly decreased after NORAD knockdown compared with the si-NC group of cells (Figure 5; P < 0.05).
Figure 5.

Knockdown of NORAD decreased PC-3 and DU145 cell migration according to a wound healing assay. Data are representative of three experiments; results are means ± SD. *P < 0.05.

Knockdown of NORAD decreased PC-3 and DU145 cell migration according to a wound healing assay. Data are representative of three experiments; results are means ± SD. *P < 0.05.

Discussion

Despite many advances in early diagnosis and treatment strategy developments, PCA remains a lethal disease. In this study, our data showed that NORAD expression was induced in PCA cell lines, which consequently increased their proliferation and migration ability. These results imply the existence of a mechanistic relationship between NORAD and PCA. According to past research, NORAD overexpression is associated with poor prognosis in many types of cancer patients.[18-20] NORAD is extensively overexpressed in cervical cancer, which induces cervical cancer progression. Additionally, NORAD induces the transforming growth factor-β pathway and modulates the progression of epithelial–mesenchymal transition progression in lung cancer.[21] To the best of our knowledge, no previous study has investigated the effect of NORAD on PCA cells. To examine the impact of NORAD on PCA, its expression was knocked down in PC3 and DU145 cells using siRNA. Consistent with a previous report,[22] our observations indicated that silencing NORAD significantly suppressed the PCA cell proliferation and migration capacity and increased cell apoptosis. In conclusion, we found that NORAD facilitated the metastasis and proliferation of PCA. However, although our data provide new insights into the roles of NORAD in PCA cells, the underlying mechanisms require further investigation.
  22 in total

1.  Long-term Outcomes Following Radiation Therapy For Prostate Cancer Patients With Lymph Node Metastases at Diagnosis Treated With and Without Surgery.

Authors:  Gilles Crehange; Alejandra Izaguirre; Vivian Weinberg; Charles C Hsu; Alexander R Gottschalk; I-Chow Hsu; Katsuto Shinohara; Peter Carroll; Mack Roach
Journal:  Am J Clin Oncol       Date:  2016-04       Impact factor: 2.339

2.  NORAD Expression Is Associated with Adverse Prognosis in Esophageal Squamous Cell Carcinoma.

Authors:  Xiaoliang Wu; Zuan-Fu Lim; Zhongwen Li; Ling Gu; Wenjuan Ma; Qianghua Zhou; Huifang Su; Xing Wang; Xianzi Yang; Zhenfeng Zhang
Journal:  Oncol Res Treat       Date:  2017-05-10       Impact factor: 2.825

3.  The lncRNA NEAT1 facilitates cell growth and invasion via the miR-211/HMGA2 axis in breast cancer.

Authors:  Xuerui Li; Shuxia Wang; Zhenzhong Li; Xiaoyu Long; Zibai Guo; Guochun Zhang; Jian Zu; Yu Chen; Linzhu Wen
Journal:  Int J Biol Macromol       Date:  2017-07-16       Impact factor: 6.953

4.  High expression of long noncoding RNA NORAD indicates a poor prognosis and promotes clinical progression and metastasis in bladder cancer.

Authors:  Qiaqia Li; Chao Li; Jinbo Chen; Peihua Liu; Yu Cui; Xinyi Zhou; Huihuang Li; Xiongbing Zu
Journal:  Urol Oncol       Date:  2018-03-28       Impact factor: 3.498

5.  Knockdown of long non-coding RNA XIST inhibits cell viability and invasion by regulating miR-137/PXN axis in non-small cell lung cancer.

Authors:  Huijuan Jiang; Hongzhi Zhang; Xigang Hu; Wenbo Li
Journal:  Int J Biol Macromol       Date:  2018-01-11       Impact factor: 6.953

6.  Comparative analysis of oncologic outcomes for open vs. robot-assisted radical prostatectomy in high-risk prostate cancer.

Authors:  Donghyun Lee; Seung-Kwon Choi; Jinsung Park; Myungsun Shim; Aram Kim; Sangmi Lee; Cheryn Song; Hanjong Ahn
Journal:  Korean J Urol       Date:  2015-07-29

7.  Characteristics of prostate cancer detection rate (PCDR) in Chinese Han population under different prostate biopsy methods.

Authors:  Yongsheng Pan; Bianjiang Liu; Yuan Huang; Jun Wang; Xiao Li; Cheng Zhang; Jie Wu; Yuxiao Zheng; Chao Qin; Gong Cheng; Lixin Hua; Zengjun Wang
Journal:  Oncotarget       Date:  2017-05-16

8.  Long noncoding RNA NORAD, a novel competing endogenous RNA, enhances the hypoxia-induced epithelial-mesenchymal transition to promote metastasis in pancreatic cancer.

Authors:  Hongzhe Li; Xinjing Wang; Chenlei Wen; Zhen Huo; Weishen Wang; Qian Zhan; Dongfeng Cheng; Hao Chen; Xiaxing Deng; Chenghong Peng; Baiyong Shen
Journal:  Mol Cancer       Date:  2017-11-09       Impact factor: 27.401

9.  Long noncoding RNA NORAD regulates transforming growth factor-β signaling and epithelial-to-mesenchymal transition-like phenotype.

Authors:  Natsumi Kawasaki; Toshiki Miwa; Satoshi Hokari; Tsubasa Sakurai; Kazuho Ohmori; Kensuke Miyauchi; Kohei Miyazono; Daizo Koinuma
Journal:  Cancer Sci       Date:  2018-05-29       Impact factor: 6.716

10.  lncRNA NORAD Contributes to Colorectal Cancer Progression by Inhibition of miR-202-5p.

Authors:  Jie Zhang; Xiao-Yan Li; Ping Hu; Yuan-Sheng Ding
Journal:  Oncol Res       Date:  2018-02-22       Impact factor: 5.574

View more
  9 in total

1.  Long non-coding RNA NORAD exhaustion represses prostate cancer progression through inhibiting TRIP13 expression via competitively binding to miR-495-3p.

Authors:  Fengling Chen; Ling Liu; Shuya Wang
Journal:  Cancer Cell Int       Date:  2020-07-18       Impact factor: 5.722

2.  Long non-coding RNA NORAD induces phenotypic regulation of vascular smooth muscle cells through regulating microRNA-136-5p-targeted KDM1A.

Authors:  Chao Lv; Jun Wang; Shuhui Dai; Yanwei Chen; Xiaofan Jiang; Xia Li
Journal:  Cell Cycle       Date:  2021-09-29       Impact factor: 5.173

3.  NORAD regulates epithelial‑mesenchymal transition of non‑small cell lung cancer cells via miR‑422a.

Authors:  Zhikun Chen; Qin Che; Chunxue Xie
Journal:  Mol Med Rep       Date:  2020-12-10       Impact factor: 2.952

4.  Long non-coding RNA NORAD promotes the prostate cancer cell extracellular vesicle release via microRNA-541-3p-regulated PKM2 to induce bone metastasis of prostate cancer.

Authors:  Chuan-Yi Hu; Juan Chen; Xin-Hua Qin; Pan You; Jie Ma; Jing Zhang; He Zhang; Ji-Dong Xu
Journal:  J Exp Clin Cancer Res       Date:  2021-03-16

5.  Silencing the lncRNA NORAD inhibits EMT of head and neck squamous cell carcinoma stem cells via miR‑26a‑5p.

Authors:  Weiming Hu; Yong Zhao; Lizhong Su; Zuliang Wu; Wenjing Jiang; Xiaoze Jiang; Ming Liu
Journal:  Mol Med Rep       Date:  2021-08-26       Impact factor: 2.952

Review 6.  Crosstalk between Long Non Coding RNAs, microRNAs and DNA Damage Repair in Prostate Cancer: New Therapeutic Opportunities?

Authors:  Folake Orafidiya; Lin Deng; Charlotte Lynne Bevan; Claire Emily Fletcher
Journal:  Cancers (Basel)       Date:  2022-01-31       Impact factor: 6.639

7.  lncRNA NORAD promotes lung cancer progression by competitively binding to miR-28-3p with E2F2.

Authors:  Wenjun Mao; Shengfei Wang; Ruo Chen; Yijun He; Rongguo Lu; Mingfeng Zheng
Journal:  Open Med (Wars)       Date:  2022-09-28

8.  Long non-coding RNA NORAD inhibition upregulates microRNA-323a-3p to suppress tumorigenesis and development of breast cancer through the PUM1/eIF2 axis.

Authors:  Pengfei Shi; Jiaming Zhang; Xun Li; Wenhuan Li; Hai Li; Peng Fu
Journal:  Cell Cycle       Date:  2021-06-14       Impact factor: 5.173

9.  Silencing of Long Non-Coding RNA (LncRNA) Non-Coding RNA Activated by DNA Damage (NORAD) Inhibits Proliferation, Invasion, Migration, and Promotes Apoptosis of Glioma Cells via Downregulating the Expression of AKR1B1.

Authors:  Lun Luo; Chuan Chen; Haiyong He; Meiqin Cai; Cong Ling
Journal:  Med Sci Monit       Date:  2020-07-21
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.